Anti-CD7 CAR T Cells SenL-T7 clinical trials
How each study uses Anti-CD7 CAR T Cells SenL-T7 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD7 CAR T Cells SenL-T7 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Senl-T7
- 3
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD7 CAR T Cells SenL-T7.
- Oct 2027Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBLNot applicable · Hebei Senlang Biotechnology Inc., Ltd.
Studies
Open first, then newest update. How each study uses Anti-CD7 CAR T Cells SenL-T7 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBLRecruitingNot applicableHebei Senlang Biotechnology Inc., Ltd.NCT05626400Written as Senl-T7
- Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaStatus unknownNot applicableHebei Senlang Biotechnology Inc., Ltd.NCT04916860Written as Senl-T7
- Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ LymphomaStatus unknownNot applicableHebei Senlang Biotechnology Inc., Ltd.NCT04928105Written as Senl-T7